Does tirzepatide lower blood pressure?

Yes, average blood pressure fell in several tirzepatide trials, especially alongside weight loss. In the SURMOUNT-1 24-hour substudy, systolic pressure was about 7 to 10 mmHg lower than placebo after 36 weeks across the three treatment groups. That is an average, not a promise about any one person's reading, and the study did not test tirzepatide as a replacement for hypertension treatment.

How much can blood pressure drop on tirzepatide?

The best 24-hour data found placebo-adjusted systolic reductions of 7.4, 10.6, and 8.0 mmHg across three tirzepatide groups at week 36. In the full SURMOUNT-1 trial, the average difference at week 72 was 6.8 mmHg systolic and 4.2 mmHg diastolic. Individual changes can be smaller, larger, or absent.

Can tirzepatide make blood pressure too low?

It can. In SURMOUNT-1, hypotension was reported in 1.0% of tirzepatide participants and orthostatic hypotension in 0.6%. Dizziness was more common, at 4.6%, although dizziness can also come from dehydration or low blood sugar. Faintness after standing, repeated low readings, or new weakness deserves clinical review rather than an automatic medication change.

What if I already take blood-pressure medicine?

Existing blood-pressure medicine makes follow-up more important because its effect can add to a treatment-related drop. The current Zepbound label reports low-pressure events in 2.2% of people taking those medicines and 1.2% of those who were not. A prescriber may review repeat readings, symptoms, dehydration, and the full medication list before adjusting any treatment.

Why does tirzepatide affect blood pressure?

Weight loss appears to be the main reason. A SURMOUNT-1 analysis estimated that weight change explained about 68% of the systolic reduction and 71% of the diastolic reduction. Other possible contributors include releasing more sodium through the kidneys, eating less sodium, holding less fluid, and easier relaxation of blood vessels, but the tirzepatide substudy did not measure all of those pathways directly.

Tirzepatide and Blood Pressure: Does It Lower It?

Yes. Studies of tirzepatide and blood pressure show that the top number often falls by several points during treatment. In one carefully measured trial, the average drop was about 7 to 10 mmHg compared with placebo, a look-alike treatment with no active drug. Most of that change traveled with weight loss. It isn't certain for every person, though, and a lower reading can become a problem when it brings dizziness or faintness.

Tirzepatide and blood pressure: what the trial found

The clearest picture comes from a planned part of SURMOUNT-1, a large obesity trial in adults without diabetes. Researchers enrolled 600 people in a blood-pressure substudy. Of those, 494 had usable readings both before treatment and at week 36.

Instead of relying on a single clinic reading, each person wore an ambulatory monitor, a cuff that checked pressure through the day and night. Average starting systolic pressure—the top number, showing pressure when the heart squeezes—was 124.6 mmHg.

After 36 weeks, average 24-hour systolic pressure was 7.4, 10.6, and 8.0 mmHg lower than placebo across the three tirzepatide groups. The reduction appeared in daytime and nighttime readings. Diastolic pressure—the bottom number, between heartbeats—fell by 2.0 and 2.9 mmHg in two groups; the 0.5 mmHg change in the third group was not statistically clear. These results were published in Hypertension in 2024.

There is an important boundary around those numbers. The average starting pressure was not high, everyone entered below 140/90, and blood-pressure medicines had to be stable. This was not a trial of tirzepatide as a replacement treatment for uncontrolled hypertension.

Why blood pressure may come down

Weight change explains most of the drop. In a separate analysis of all 2,539 SURMOUNT-1 participants, pressure declined mainly during the first 24 weeks and then leveled out. At week 72, tirzepatide groups averaged 6.8 mmHg lower systolic pressure and 4.2 mmHg lower diastolic pressure than placebo. Weight loss accounted for about 68% and 71% of those changes, respectively, according to the 2024 Heart analysis.

That makes everyday sense. Losing body mass can ease the work placed on the heart and blood vessels. Improved insulin response can also reduce some of the signals that tell the kidneys to hold on to salt and water.

The drug may have smaller direct effects too. Tirzepatide activates GLP-1 and GIP receptors, protein switches that respond to gut hormones after a meal. In a small human experiment, GLP-1 increased natriuresis, meaning the kidneys released more sodium into urine (Journal of Clinical Endocrinology & Metabolism, 2004). Less retained sodium and water can ease pressure. Another small human trial found that GLP-1 helped the lining of blood vessels relax (American Journal of Physiology-Endocrinology and Metabolism, 2007).

Those pathways are plausible, not settled facts about tirzepatide. The 24-hour substudy did not measure food sodium or urine sodium, so it could not separate eating less salt, losing weight, and a direct drug effect. How tirzepatide works explains the two hormone signals without the shorthand.

What the newest evidence adds

As of September 6, 2026, the day this article was written, an August 15, 2026 meta-analysis had pooled 32 randomized trials with 47,332 participants. Tirzepatide was associated with fewer high-pressure events, but low-pressure events were reported 2.45 times as often as in comparison groups. A pooled result shows a pattern across trials; it cannot predict one person's next reading.

The same analysis found no statistically clear difference in high- or low-pressure events with semaglutide. That does not make semaglutide a blood-pressure substitute or prove it is the better choice. The medicines differ in more than this one outcome, as the tirzepatide and semaglutide comparison lays out.

The flip side: lightheadedness and low readings

A lower number is not automatically a better number. It matters how a person feels and what other medicines are already lowering pressure. Orthostatic hypotension—pressure that drops after standing—can feel like a head rush, dim vision, weakness, or unsteadiness.

In the 72-week SURMOUNT-1 analysis, blood-pressure-related side effects occurred in 6.8% of tirzepatide participants and 3.3% of placebo participants. Dizziness was the most common, affecting about 1 in 22 people on tirzepatide (4.6%) versus about 1 in 43 on placebo (2.3%). Hypotension was reported in 1.0%, and orthostatic hypotension in 0.6%. Severe or serious events were uncommon, at 0.2%.

The current Zepbound prescribing information adds a useful practical detail. Across two trials, low-pressure events occurred in 2.2% of people who also took blood-pressure medicine and 1.2% of those who did not. Some cases happened alongside nausea, vomiting, diarrhea, and dehydration.

That overlap is why a symptom alone does not reveal the cause. Lightheadedness can come from low pressure, dehydration, or low blood sugar. A prescriber may look at repeat readings, recent stomach side effects, fluid intake, and the complete medication list before deciding what should change. Blood-pressure medicine should not be stopped or changed without that clinician's plan. Fainting, chest pain, trouble breathing, confusion, or stroke-like symptoms need urgent care.

For the broader side-effect picture, see tirzepatide side effects.

What a provider may watch over time

A single low reading can be noise. A repeated pattern, especially with symptoms, is more useful. A provider may ask for home readings taken under similar conditions and may compare a seated reading with one after standing.

The rest of the picture matters too: the starting pressure, how much it has changed, current blood-pressure drugs, kidney or heart conditions, and any fluid loss from stomach side effects. If readings keep falling, the provider may adjust another pressure-lowering medicine. That decision is individual; the trial averages do not supply a personal target.

Where compounded tirzepatide fits

The trials above studied manufactured tirzepatide, not Promise's compounded formulation. Promise dispenses tirzepatide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

The sensible takeaway is modest: tirzepatide has been associated with lower average blood pressure in trials, but it is not a reason to manage hypertension without medical care. At Promise, a licensed provider reviews every request, and not everyone qualifies. That review is also where existing pressure medicines and new lightheadedness belong.